FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ: OMCL) (“Omnicell”) today announced that it intends to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of Convertible Senior Notes due 2029 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

德克萨斯州沃思堡——（商业新闻短讯）——Omnicell，Inc.（纳斯达克代码：OMCL）（“Omnicell”）今天宣布，根据市场条件和其他因素，它打算以私募形式（以下简称“发售”）向合理认为是符合1933年《证券法》修订版（以下简称“证券法”）第144A条规定的合格机构买家的人士发售2029年到期的可转换优先票据（以下简称“票据”）本金总额1.5亿美元。

Omnicell also intends to grant the initial purchasers of the notes an option to purchase, during a 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $22.5 million aggregate principal amount of notes..

Omnicell还打算授予票据的初始购买者在票据发行的第一天（包括第一天）开始的13天内购买票据的选择权，最多可额外购买2250万美元的票据本金总额。。

The notes will be general unsecured, senior obligations of Omnicell, will accrue interest payable semiannually in arrears and will mature on December 1, 2029, unless earlier converted, redeemed or repurchased. Upon conversion, Omnicell will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, shares of Omnicell’s common stock or a combination of cash and shares of Omnicell’s common stock, at Omnicell’s election, in respect of the remainder, if any, of Omnicell’s conversion obligation in excess of the aggregate principal amount of the notes being converted.

票据将是Omnicell的一般无担保优先债务，将每半年累积一次拖欠的应付利息，并将于2029年12月1日到期，除非提前转换、赎回或回购。转换后，Omnicell将支付高达待转换票据本金总额的现金，并支付或交付（视情况而定）现金、Omnicell普通股股份或现金与Omnicell普通股股份的组合，由Omnicell选择，以支付或交付超出待转换票据本金总额的Omnicell转换义务的剩余部分（如有）。

The interest rate, initial conversion rate, redemption or repurchase rights and other terms of the notes will be determined at the time of pricing of the offering..

票据的利率、初始转换率、赎回权或回购权和其他条款将在发行定价时确定。。

Omnicell expects to use a portion of the net proceeds from the offering to pay the cost of the convertible note hedge transactions described below (after such cost is partially offset by the proceeds to Omnicell from the sale of warrants in the warrant transactions described below). In addition, Omnicell expects to use the remaining net proceeds from the offering, together with cash on hand, to repurchase for cash up to $400.0 million aggregate principal amount of Omnicell’s outstanding 0.25% Convertible Senior Notes due 2025 (the “2025 notes”) as described below.

Omnicell预计将使用发行净收益的一部分来支付下文所述的可转换票据对冲交易的成本（该成本被下文所述权证交易中向Omnicell出售权证的收益部分抵消后）。此外，Omnicell预计将使用发行剩余的净收益以及库存现金，以现金回购Omnicell 2025年到期的未偿还0.25%可转换优先票据（“2025票据”）本金总额高达4亿美元，如下所述。

If the initial purchasers exercise their option to purchase additional notes, Omnicell expects to sell additional warrants to the option counterparties and use a portion of the net proceeds from the sale of the additional notes, together with the proceeds from the sale of additional warrants, to enter into additional convertible note hedge transactions and the remaining net proceeds for repurchases of the 2025 notes or for working capital and other general corporate purposes..

如果初始购买者行使购买额外票据的期权，Omnicell预计将向期权交易对手出售额外认股权证，并将出售额外票据的净收益的一部分与出售额外认股权证的收益一起用于进行额外的可转换票据对冲交易，剩余的净收益用于回购2025年票据或用于营运资本和其他一般公司目的。。

In connection with the pricing of the notes, Omnicell expects to enter into convertible note hedge transactions with one or more of the initial purchasers or their respective affiliates and/or other financial institutions (the “option counterparties”). Omnicell also expects to enter into warrant transactions with the option counterparties.

关于票据的定价，Omnicell预计将与一个或多个初始购买者或其各自的关联公司和/或其他金融机构（“期权交易对手”）进行可转换票据对冲交易。Omnicell还希望与期权交易对手进行权证交易。

The convertible note hedge transactions are expected generally to reduce the potential dilution to Omnicell’s common stock upon any conversion of notes and/or offset any cash payments Omnicell is required to make in excess of the principal amount of converted notes, as the case may be. However, the warrant transactions could separately have a dilutive effect on Omnicell’s common stock to the extent that the market price per share of Omnicell’s common stock exceeds the strike price of the warrants.

可转换票据对冲交易通常会在任何票据转换时减少对Omnicell普通股的潜在稀释，和/或抵消Omnicell需要支付的超过转换票据本金金额的任何现金付款（视情况而定）。但是，如果Omnicell普通股每股市场价格超过权证的执行价格，权证交易可能会单独对Omnicell普通股产生稀释作用。

If the initial purchasers exercise their option to purchase additional notes, Omnicell expects to enter into additional convertible note hedge transactions and additional warrant transactions with the option counterparties..

如果初始购买者行使其购买额外票据的期权，Omnicell预计将与期权交易对手进行额外的可转换票据对冲交易和额外的认股权证交易。。

In connection with establishing their initial hedges of the convertible note hedge and warrant transactions, Omnicell expects the option counterparties or their respective affiliates to enter into various derivative transactions with respect to Omnicell’s common stock and/or purchase shares of Omnicell’s common stock concurrently with or shortly after the pricing of the notes.

在建立可转换票据套期保值和权证交易的初始套期保值方面，Omnicell预计期权交易对手或其各自的关联公司将在票据定价的同时或之后不久，就Omnicell的普通股和/或购买Omnicell的普通股进行各种衍生交易。

This activity could increase (or reduce the size of any decrease in) the market price of Omnicell’s common stock or the notes at that time..

这项活动可能会增加（或减少任何下跌的规模）当时Omnicell普通股或票据的市场价格。。

In addition, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Omnicell’s common stock and/or purchasing or selling Omnicell’s common stock or other securities of Omnicell in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so in connection with any conversion, redemption or repurchase of the notes).

此外，期权交易对手或其各自的关联公司可以通过在票据定价之后和票据到期之前（并且可能与票据的任何转换、赎回或回购相关）在二级市场交易中订立或解除与Omnicell普通股有关的各种衍生工具和/或买卖Omnicell普通股或Omnicell其他证券来修改其对冲头寸。

This activity could also cause or avoid an increase or a decrease in the market price of Omnicell’s common stock or the notes, which could affect a noteholder’s ability to convert the notes and, to the extent the activity occurs during any observation period related to a conversion of notes, it could affect the number of shares of Omnicell’s common stock, if any, and value of the consideration, if any, that a noteholder will receive upon conversion of the notes..

这项活动还可能导致或避免Omnicell普通股或票据市场价格的上涨或下跌，这可能会影响票据持有人转换票据的能力，并且如果该活动发生在与票据转换相关的任何观察期内，则可能会影响Omnicell普通股的股份数量（如果有的话）以及票据持有人在转换票据时将收到的对价（如果有的话）的价值。。

Concurrently with the pricing of the notes in the offering, Omnicell expects to enter into one or more separate and individually negotiated transactions with certain holders of the 2025 notes to repurchase for cash up to $400.0 million aggregate principal amount of its 2025 notes (the “note repurchases”).

。

The terms of the note repurchases are anticipated to be individually negotiated with each holder of the 2025 notes and will depend on several factors, including the market price of Omnicell’s common stock and the trading price of the 2025 notes at the time of such note repurchases. No assurance can be given as to how much, if any, of the 2025 notes will be repurchased or the terms on which they will be repurchased.

。无法保证2025年票据的回购金额（如有）或回购条款。

Omnicell expects to negotiate the note repurchases through one of the initial purchasers and/or its affiliate. This press release is not an offer to repurchase the 2025 notes and the offering of the notes is not contingent upon the repurchase of the 2025 notes. Omnicell may also repurchase additional outstanding 2025 notes following the completion of the offering..

Omnicell希望通过其中一位初始购买者和/或其关联公司谈判票据回购。本新闻稿并非回购2025年票据的要约，票据的发行不取决于回购2025年票据。Omnicell还可能在发行完成后回购额外的未偿还2025年票据。。

Omnicell expects that holders of the 2025 notes that are repurchased by Omnicell as described above may enter into or unwind various derivatives with respect to Omnicell’s common stock (including entering into derivatives with one or more of the initial purchasers in the offering or their respective affiliates) and/or purchase or sell shares of Omnicell’s common stock concurrently with or shortly after the pricing of the notes..

Omnicell预计，上述由Omnicell回购的2025年票据持有人可以在票据定价的同时或之后不久，签订或解除与Omnicell普通股相关的各种衍生工具（包括与发行中的一个或多个初始购买者或其各自的关联公司签订衍生工具）和/或购买或出售Omnicell普通股的股票。。

In connection with the issuance of the 2025 notes, Omnicell entered into convertible note hedge transactions (the “existing convertible note hedge transactions”) and warrant transactions (the “existing warrant transactions” and, together with the existing convertible note hedge transactions, the “existing call spread transactions”) with one of the initial purchasers and certain financial institutions (the “existing counterparties”).

关于2025年票据的发行，Omnicell与其中一名初始购买者和某些金融机构（“现有交易对手”）签订了可转换票据对冲交易（“现有可转换票据对冲交易”）和权证交易（“现有权证交易”，以及与现有可转换票据对冲交易一起的“现有看涨期权交易”）。

To the extent Omnicell repurchases any 2025 notes, it may enter into agreements with the existing counterparties concurrently with or shortly after the pricing of this offering to unwind a portion of the existing convertible note hedge transactions in a notional amount corresponding to the principal amount of the 2025 notes so repurchased.

在Omnicell回购任何2025年票据的情况下，它可以在本次发行定价的同时或之后不久与现有交易对手签订协议，以解除部分现有可转换票据对冲交易，其名义金额与所回购的2025年票据的本金金额相对应。

In addition, Omnicell may enter into agreements with the existing counterparties concurrently with or shortly after the pricing of this offering to unwind a portion of the existing warrant transactions with respect to a number of shares of Omnicell’s common stock equal to the notional shares underlying such 2025 notes so repurchased..

此外，Omnicell可能在本次发行定价的同时或之后不久与现有交易对手签订协议，以解除Omnicell普通股的部分现有认股权证交易，这些股票相当于回购的2025年票据的名义股票。。

In connection with such terminations and the related unwinding of the existing hedge position of the existing counterparties with respect to such transactions, such existing counterparties and/or their respective affiliates may sell shares of Omnicell’s common stock in secondary market transactions and/or unwind various derivative transactions with respect to Omnicell’s common stock concurrently with or shortly after the pricing of the notes..

就此类终止和现有交易对手对此类交易的现有对冲头寸的相关平仓而言，此类现有交易对手和/或其各自的关联公司可在二级市场交易中出售Omnicell普通股的股份和/或在票据定价的同时或之后不久平仓Omnicell普通股的各种衍生交易。。

The repurchases of the 2025 notes and any unwind of the existing call spread transactions described above, and the potential related market activities by holders of the 2025 notes that are repurchased by Omnicell and the existing counterparties, as applicable, could increase (or reduce the size of any decrease in) or decrease (or reduce the size of any increase in) the market price of Omnicell’s common stock, which may affect the trading price of the notes offered in the offering at that time and, to the extent effected concurrently with the pricing of this offering, the initial conversion price of the notes.

2025年票据的回购和上述现有看涨期权差价交易的任何平仓，以及由Omnicell和现有交易对手回购的2025年票据持有人的潜在相关市场活动（如适用），可能会增加（或减少任何减少的规模）或减少（或减少任何增加的规模）Omnicell普通股的市场价格，这可能会影响当时发行的票据的交易价格，并在与本次发行定价同时影响的范围内，影响票据的初始转换价格。

Omnicell cannot predict the magnitude of such market activity or the overall effect it will have on the price of the notes offered in the offering or its common stock..

Omnicell无法预测此类市场活动的规模，也无法预测其对发售票据或其普通股价格的整体影响。。

Neither the notes, nor the shares of Omnicell’s common stock issuable upon conversion of the notes, if any, have been, or will be, registered under the Securities Act or any state securities laws, and unless so registered, may not be offered or sold in the United States or to, or for the account or benefit of, U.S.

票据或票据转换后可发行的Omnicell普通股股份（如有）均未或将未根据《证券法》或任何州证券法进行登记，除非进行登记，否则不得在美国境内或向美国境内发售或出售。

persons, absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws..

未注册或适用豁免的人员，或在不受《证券法》和其他适用证券法注册要求约束的交易中。。

This press release is neither an offer to sell nor a solicitation of an offer to buy any securities, nor shall it constitute an offer to sell, solicitation of an offer to buy or sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿既不是出售要约，也不是邀请购买任何证券的要约，也不构成在任何州或司法管辖区的证券法律登记或资格之前，在任何州或司法管辖区内出售、邀请购买或出售任何证券的要约，在该州或司法管辖区内，此类要约、邀请或出售将是非法的。。

About Omnicell

关于Omnicell

Since 1992, Omnicell has been committed to transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics, smart devices, intelligent software, and expert services, Omnicell solutions are helping healthcare facilities worldwide to reduce costs, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry vision of the Autonomous Pharmacy..

自1992年以来，Omnicell一直致力于通过以结果为中心的创新来改变药学服务，旨在优化所有护理环境中的临床和业务结果。通过机器人、智能设备、智能软件和专家服务的综合组合，Omnicell解决方案正在帮助全球医疗机构降低成本，提高劳动效率，建立新的收入流，加强供应链控制，支持合规性，并更接近自主药房的行业愿景。。

Forward-Looking Statements

前瞻性声明

This press release contains “forward-looking” statements that involve risks and uncertainties, including statements concerning the proposed terms of the notes, the convertible note hedge and warrant transactions, the note repurchases and the unwind of the existing call spread transactions, the completion, timing and size of the proposed offering of the notes and the convertible note hedge and warrant transactions, the anticipated use of proceeds from the offering, including the proposed note repurchases, and the potential impact of the foregoing or related transactions on dilution to holders of Omnicell’s common stock, and the market price of Omnicell’s common stock or the notes or the conversion price of the notes.

本新闻稿包含涉及风险和不确定性的“前瞻性”声明，包括关于票据拟议条款、可转换票据对冲和权证交易、票据回购和现有看涨期权交易的解除、票据拟议发行和可转换票据对冲和权证交易的完成、时间和规模、包括拟议票据回购在内的发行收益的预期用途、上述或相关交易对Omnicell普通股持有人稀释的潜在影响以及Omnicell普通股或票据的市场价格或票据的转换价格的声明。

Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from Omnicell’s plans. These risks include, but are not limited to, market risks, trends and conditions, Omnicell’s ability to complete the proposed offering on the expected terms, or at all, whether Omnicell will be able to satisfy closing conditions related to the proposed offering, whether and on what terms Omnicell may repurchase any of the 2025 notes, changes in the structure or terms of the convertible note hedge and warrant transactions, changes in the structure or terms of the unwind of the existing call spread transactions and unanticipated uses of capital and those risks included in the section titled “Risk Factors” in Omnicell’s Securities and Exchange Commission (“SEC”) filings and reports, including its Annual Report on Form 10-K for the year ended December 31, 2023 and other filings that Omnicell makes from time to time with the SEC, which are available on the SEC’s website at www.sec.gov.

此类前瞻性陈述涉及已知和未知的风险、不确定性和其他因素，这些因素可能导致实际事件与Omnicell的计划存在重大差异。这些风险包括但不限于市场风险、趋势和条件、Omnicell按预期条款完成拟议发行的能力，或Omnicell是否能够满足与拟议发行相关的交割条件、Omnicell是否以及以何种条款回购2025年票据、可转换票据对冲和权证交易的结构或条款的变化、现有看涨期权差价交易的解除结构或条款的变化以及资本的意外使用，以及Omnicell证券交易委员会（“SEC”）文件和报告中标题为“风险因素”的部分所包含的风险，包括其截至12月的10-K表年度报告31、2023以及Omnicell不时向SEC提交的其他文件，可在SEC网站www.SEC.gov上查阅。

All forwar.

一切为了战争。

OMCL-E

OMCL-E